Professional
Added to YB: 2026-05-15
Pitch date: 2026-04-22
LQDA [neutral]
Liquidia Corporation
+53.6%
current return
Author Info
Laughing Water Capital is a boutique investment partnership. Our partners believe that careful analysis of a select group of businesses can lead to above average investment returns for equity investors. Our small size and patient approach give us an advantage that cannot be matched by traditional asset managers or hedge funds that are focused on the day to day gyrations of the stock market, rather than the fundamental value of businesses. Visit their website.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$5.1B
Pitch Price
$36.85
Price Target
115.20 (+104%)
Dividend
N/A
EV/EBITDA
106.09
P/E
235.90
EV/Sales
17.65
Sector
Pharmaceuticals
Category
special_situation
Laughing Water Capital Portfolio Holding: Liquidia Corporation
LQDA (holding update): YUTREPIA sales launch exceeding expectations despite ongoing patent battle w/ UTHR. Delayed judge ruling likely favorable per legal experts; if won, continued adoption could yield >$1.2B revenue run rate by YE. Even unfavorable ruling allows PAH market share gain. Trading at discount to UTHR sales multiple; fair value 2x+ current. Prime M&A target as Big Pharma faces $300B patent cliff w/ $1T dry powder.
Read full article (2 min)